Genocea HSV-2 Immunotherapeutic GEN-003 Elicits Significant, Durable T Cell Responses in Vaccinated Subjects

Immunogenicity Data from Phase 1/2a Trial Highlighted at 39th Annual International Herpesvirus Workshop July 22, 2014 Genocea Biosciences, Inc., a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today presented data from a Phase 1/2a study of GEN-003, the Company’s investigational immunotherapy against HSV-2, demonstrating that the immunotherapy elicited T cell, IgG and neutralizing antibody responses that remained significantly above …

Genocea Commences Phase 2 Dose Optimization Trial for GEN-003 HSV-2 Immunotherapy

July 21, 2014 Genocea Biosciences, Inc., a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced the start of a Phase 2 dose optimization trial for GEN-003, the Company’s immunotherapy candidate against herpes simplex-type 2 (HSV-2). “Consistent with our long-standing development plans, this Phase 2 trial will compare the best dose of GEN-003 from our Phase 1/2a trial …

Genocea Announces Positive Top-Line 12-Month Follow-up Data from Phase 1/2a Clinical Trial for HSV-2 Immunotherapy GEN-003

Full Data in Oral Presentation at Major Infectious Disease Medical Meeting in October 2014 June 1, 2014 Genocea Biosciences, Inc., a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced positive top-line 12-month follow-up data from a Phase 1/2a study of GEN-003, the Company’s immunotherapy candidate against herpes simplex virus type 2 (HSV-2). At 12 months after the …

Published data supports innovative HSV-2 therapeutic vaccine GEN-003

Genocea Biosciences have announced the publication of preclinical trial results for their investigational therapeutic HSV-2 vaccine. The results, published in Journal of Virology, show that vaccination with GEN-003 and Isconova AB's Matrix-M adjuvant was capable of inducing antigen- and virus-specific immune responses. The vaccine improved outcomes in preclinical models of HSV-2 disease. GEN-003 showed a significant impact on viral shedding …